Did Allergan lose its $2.1B Kythera bet? by Carly Helfand Tuesday, November 7, 2017 Over two years ago, Bernstein analyst Ronny Gal wrote that Allergan “obviously” has “much higher expectations than we do” for chin-fat drug Kybella.
Allergan shells out $2.5B for fat-freezing tech by Eric Sagonowsky Monday, February 13, 2017 Allergan unveiled its latest “stepping-stone deal” Monday: The "fat freezing" company Zeltiq, a $2.47 billion add-on for its aesthetics business.
Allergan brand, rebates prime aesthetics biz for growth by Carly Helfand Thursday, June 30, 2016 Good news for Allergan: The aesthetics market--which has lately been on the rise--is showing no signs of slowing down.
